Company Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders.
Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
The company’s preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.
Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
| Country | United States |
| Founded | 2016 |
| IPO Date | Feb 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jatinder Dhaliwal |
Contact Details
Address: 1055 Westlakes Drive, Suite 300 Berwyn, Pennsylvania 19312 United States | |
| Phone | 610 727 4597 |
| Website | virpaxpharma.com |
Stock Details
| Ticker Symbol | VRPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001708331 |
| CUSIP Number | 928251206 |
| ISIN Number | US9282512063 |
| Employer ID | 82-1510982 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jatinder Dhaliwal | Chief Executive Officer |
| Usama Chaudhry | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 8-K | Current Report |
| Dec 9, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 29, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 20, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |